Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Endovascular Aneurysm Repair

PharmaDeviceNews Endovascular Aneurysm Repair

Medical Devices & Diagnostics

Shape Memory Medical completes AAA-SHAPE trial enrollment for aneurysm sac device

by Pallavi Madhiraju
July 8, 2026
0 Comments

Find out how Shape Memory Medical’s AAA-SHAPE trial could reshape aneurysm sac management after EVAR.

Read More

Latest news and features

Akamis Bio completes 33-patient NG-350A rectal cancer trial after early 50% response
Coya’s ALS trial has enrolled 120 patients. Why is it extending COYA 302 treatment before results arrive?
One blood sample, 68,000 possible pathogens: Can Delve Bio speed up infection diagnosis?
Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?
Gilead is betting nearly $1.9bn on masked cancer drugs. What makes Vir’s technology different?
The FDA rejected tab-cel twice. Can Atara’s third review finally deliver approval?
Sarepta’s RNA therapy reaches the nucleus in myotonic dystrophy models. Can it restore muscle function?
Cyted Health’s EndoSign detects Barrett’s esophagus with 90% sensitivity in US study
JCR’s enzyme therapy reaches Kuwait. Can crossing the blood-brain barrier change Hunter syndrome care?
Can Estrella’s EB103 challenge established CAR-T therapies in B-cell lymphoma?
FDA expands ANKTIVA approval to papillary-only bladder cancer after BCG failure
Aptar’s nasal vaccine device is now CE marked. Could it help bring more needle-free vaccines to market?

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Pulsed field ablation is emerging as a nonthermal alternative to radiofrequency and cryoballoon ablation, using targeted electrical pulses to isolate pulmonary veins while potentially reducing collateral tissue injury in atrial fibrillation treatment. Representative image.

Pharma & Biotech

Novartis pelacarsen fails 8,323-patient Phase 3 Lp(a)HORIZON cardiovascular trial

September 6, 2026

Latest business and industry news

Universal Music loses Republic and Def Jam chiefs as €250m cost reset reaches labels
Proofpoint to acquire Varonis for $6.3bn as Thoma Bravo targets AI security market
BlackRock’s $15.5tn asset milestone reveals why private markets and ETFs are reshaping its growth
Equinor targets rapid Grimsnes oil development after new North Sea discovery
Mondi shares plunge as €196m quarterly EBITDA masks fresh packaging margin pressure

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.